|
|
|
|
Cancellation of Acomplia(rimonabant) Registration in Jordan
On 26 February 2009 Jordan Food and Drug Adminstration (according to Drug and Pharmacy Law/article 17 B) issued a decision of cancellation the registration of Acomplia (rimonabant), because till now the risks out weigh its benefits, knowing that JFDA has suspended earlier the usage of
Acomplia tablets (Rimonabant) which is used for the treatment of obesity and overweight patients with risk factors.
Acomplia is a prescription only medicine that has been authorized in EUsince 2006.
The Emea's Committee for Medicinal Products for Human Use has concluded, based on evaluation of new data from post-marketing experience regarding psychiatric effects, that the benefits of Acomplia no longer out weigh its risks
Acomplia was registered last April, but was not marketed in Jordan |
|
|
|